Leann Silhan
Pulmonary Disease · Dallas, TXNPI 1952436172
Payments from drug & device makers
What this record shows
This record is dominated by grants: $1,000 of the $1,635 with a category attached, or 61.2%. Genentech, Inc. accounts for 61.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2020 at $1,000 and has fallen 86.8% since, to $132 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 35 payments — averaging $46.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$1K
- AbbVie$92
- Cleerly, Inc.$57
- Exact Sciences$56
- GSK$39
- Novo Nordisk$37
- plus $354 from 15 others
Across 4 payments — averaging $12,080 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$48K
What the payments were for
- Grants$1,00061%
- Food & beverage$63539%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $1,000 |
| AbbVie | 5 | $92 |
| Cleerly, Inc. | 1 | $57 |
| Exact Sciences | 3 | $56 |
| GSK | 2 | $39 |
| Novo Nordisk | 2 | $37 |
| Boehringer Ingelheim | 2 | $35 |
| Pfizer | 2 | $35 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Antares Pharma, Inc. | 2 | $32 |
| Genentech USA, Inc. | 3 | $32 |
| Merck | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $23 |
| Perspectum Diagnostics Ltd | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| Echosens North America, Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Halozyme Inc | 1 | $13 |
How this compares
$1,635 in reported general payments places this provider in the 45th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $243,565 |
| OfevNintedanib Esylate | 11 | $140,792 |
| CreonLipase/Protease/Amylase | 14 | $16,780 |
| EliquisApixaban | 16 | $11,831 |
| Tadalafil | 12 | $8,214 |
| DayvigoLemborexant | 11 | $5,718 |
| Enoxaparin Sodium | 12 | $3,369 |
| Doxycycline Hyclate | 11 | $398 |
| Gabapentin | 14 | $339 |
| Mirtazapine | 25 | $295 |
| Metformin Hcl | 12 | $253 |
| Losartan Potassium | 30 | $227 |
| Bupropion XlBupropion Hcl | 15 | $191 |
| Rosuvastatin Calcium | 21 | $166 |
| Atorvastatin Calcium | 15 | $130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $21 | $243,56513 claims |
| Boehringer IngelheimOfev | $35 | $140,79211 claims |
| AbbVieCreon | $92 | $16,78014 claims |
| PfizerEliquis | $35 | $11,83116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Dallas
- Yolanda MagetoDallas$239K
- Mark MillardDallas$192K
- Raksha JainDallas$153K
- Sonja BartolomeDallas$75K
- Kelly ChinDallas$72K
- Fernando TorresDallas$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.